Hyderabad: India needs diplomatic channels created by the government towards USFDA, EU or Japan to really work with regulatory agencies. There is not much pharma business happening with Japan despite India’s friendly relationship with them because of the regulatory framework, say industry experts. “There is much more than funding that government has to do on […]
Hyderabad: Indian pharma needs to move from low-risk research and innovation to high-risk research and innovation. And that’s where the country is lagging. Investing in high-risk innovation is very capital intensive and the return on that investment is both uncertain and long-term. To aid innovation, there needs to be adequate risk capital and a different […]